This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The 5-HT1B receptor - a potential target for antidepressant treatment
Psychopharmacology Open Access 15 March 2018
-
P11 promoter methylation predicts the antidepressant effect of electroconvulsive therapy
Translational Psychiatry Open Access 22 January 2018
-
Delineation of molecular pathway activities of the chronic antidepressant treatment response suggests important roles for glutamatergic and ubiquitin–proteasome systems
Translational Psychiatry Open Access 04 April 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M et al. Science 2006; 311: 77–80.
Warner-Schmidt JL, Flajolet M, Maller A, Chen EY, Qi H, Svenningsson P, Greengard P . J Neurosci 2009; 29: 1937–1946.
Oh YS, Gao P, Lee KW, Ceglia I, Seo JS, Zhang X et al. Cell 2013; 152: 831–843.
Svenningsson P, Kim Y, Warner-Schmidt J, Oh YS, Greengard P . Nat Rev Neurosci 2013; 14: 673–680.
Anisman H, Du L, Palkovits M, Faludi G, Kovacs GG, Szontagh-Kishazi P et al. J Psychiatry Neurosci 2008; 33: 131–141.
Schmidt EF, Warner-Schmidt JL, Otopalik BG, Pickett SB, Greengard P, Heintz N . Cell 2012; 149: 1152–1163.
Egeland M, Warner-Schmidt J, Greengard P, Svenningsson P . Biol Psychiatry 2010; 67: 1048–1056.
Acknowledgements
This study was supported in part by the Intramural Research Program of the National Institute of Mental Health (DM, DFI, ER, MN, AM, HM, CAZ), National Institutes of Health (IRP-NIMH-NIH), by NIMH MH090963 (PG), JPB Foundation (PG), Fisher Center for Alzheimer’s research Foundation (PG, PS) and by the Swedish Medical Research Council (PS).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
Drs Svenningsson and Greengard are coinventors of an issued patent for usage of p11 to study depression and antidepressant responses. This patent was licensed by The Rockefeller University to Intracellular Therapies, for which Drs Svenningsson and Greengard serve as consultants. Dr Manji is an employee at Johnson & Johnson. Dr Trivedi is or has been an advisor/consultant to several pharmaceutical companies (listed in the Supplementary Material). Dr Zarate is listed as a coinventor on a patent application for the use of ketamine and its metabolites in major depression. Dr Zarate has assigned his rights in the patent to the US government but will share a percentage of any royalties that may be received by the government. The remaining authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Molecular Psychiatry website
Supplementary information
PowerPoint slides
Rights and permissions
About this article
Cite this article
Svenningsson, P., Berg, L., Matthews, D. et al. Preliminary evidence that early reduction in p11 levels in natural killer cells and monocytes predicts the likelihood of antidepressant response to chronic citalopram. Mol Psychiatry 19, 962–964 (2014). https://doi.org/10.1038/mp.2014.13
Published:
Issue Date:
DOI: https://doi.org/10.1038/mp.2014.13
This article is cited by
-
Systemic immunization with altered myelin basic protein peptide produces sustained antidepressant-like effects
Molecular Psychiatry (2020)
-
P11 promoter methylation predicts the antidepressant effect of electroconvulsive therapy
Translational Psychiatry (2018)
-
The 5-HT1B receptor - a potential target for antidepressant treatment
Psychopharmacology (2018)
-
Delineation of molecular pathway activities of the chronic antidepressant treatment response suggests important roles for glutamatergic and ubiquitin–proteasome systems
Translational Psychiatry (2017)
-
Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years
Drugs (2017)